News
Centre for Chinese Herbal Medicine Drug Development and Beijing Increasepharm Corporation collaborate to develop Chinese medicine
14 September 2023
The Centre for Chinese Herbal Medicine Drug Development (CDD) has signed a strategic collaboration agreement with Beijing Increasepharm Corporation Limited (Increasepharm) for the joint development of new drugs and health products based on Chinese medicine (CM).
The agreement signing ceremony was held on 10 September. The agreement was signed by Professor Bian Zhaoxiang, Director of CDD, and Professor Zhang Baoxian, Chairman of Increasepharm. Both parties will collaborate in establishing research and development platform for the development of new CM drug products, secondary development of existing CM, technology transfer of existing products or achievements, marketing and industrialisation of existing products, with a view to promoting the inheritance, innovation, and development of CM.
About CDD and Increasepharm
Funded by the InnoHK initiative of the Innovation and Technology Commission, CDD was set up to pursue innovative CM research and development, promote CM standardisation and internationalisation, as well as turn traditional CM into novel drugs. Increasepharm is among the first batch of national high-tech enterprises, which integrates the research and development and industrialisation of drugs and health products, and holds a leading position in the research areas of new CM compound drugs, new formulations, novel CM drugs, CM clinical research service and health supplements.
Professor Bian Zhaoxiang (left) and Professor Zhang Baoxian (right) sign the strategic collaboration agreement.
Prof Xu Hongxi, Distinguished Professor of Shanghai University of Traditional Chinese Medicine (4th left), Professor Bian Zhaoxiang (5th left), Professor Zhang Baoxian (6th right), Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine (5th right), and other guests attend the signing ceremony.